A future for regulatory science in the European Union: the European Medicines Agency's strategy

P.A. Hines; R. Janssens; R. Gonzalez-Quevedo; A.I.O.M. Lambert; A.J. Humphreys

doi:10.1038/d41573-020-00032-0

A future for regulatory science in the European Union: the European Medicines Agency's strategy

P.A. Hines^*, R. Janssens, R. Gonzalez-Quevedo, A.I.O.M. Lambert, A.J. Humphreys

^*Corresponding author for this work

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

After 3 years of co-design with stakeholders and EU regulatory partners, the European Medicines Agency's Regulatory Science to 2025 strategy has been finalized. Here, we highlight the core recommendations that stakeholders deem most significant to advance evidence generation.

Original language	English
Pages (from-to)	293-294
Number of pages	2
Journal	Nature Reviews Drug Discovery
Volume	19
Issue number	5
DOIs	https://doi.org/10.1038/d41573-020-00032-0
Publication status	Published - 1 May 2020

JEL classifications

i18 - "Health: Government Policy; Regulation; Public Health"
o30 - "Technological Change; Research and Development; Intellectual Property Rights: General"

Keywords

Regulation
Medicines
Intellectual Property
Science
R&D
European Union

Access to Document

10.1038/d41573-020-00032-0

Cite this

@article{ecda9c4de243425cab6d02b1d0fd4e04,

title = "A future for regulatory science in the European Union: the European Medicines Agency's strategy",

abstract = "After 3 years of co-design with stakeholders and EU regulatory partners, the European Medicines Agency's Regulatory Science to 2025 strategy has been finalized. Here, we highlight the core recommendations that stakeholders deem most significant to advance evidence generation.",

keywords = "Regulation, Medicines, Intellectual Property, Science, R&D, European Union",

author = "P.A. Hines and R. Janssens and R. Gonzalez-Quevedo and A.I.O.M. Lambert and A.J. Humphreys",

note = "Publisher Copyright: {\textcopyright} 2020, Nature.",

year = "2020",

month = may,

day = "1",

doi = "10.1038/d41573-020-00032-0",

language = "English",

volume = "19",

pages = "293--294",

journal = "Nature Reviews Drug Discovery",

issn = "1474-1776",

publisher = "Nature Publishing Group",

number = "5",

}

TY - JOUR

T1 - A future for regulatory science in the European Union: the European Medicines Agency's strategy

AU - Hines, P.A.

AU - Janssens, R.

AU - Gonzalez-Quevedo, R.

AU - Lambert, A.I.O.M.

AU - Humphreys, A.J.

PY - 2020/5/1

Y1 - 2020/5/1

N2 - After 3 years of co-design with stakeholders and EU regulatory partners, the European Medicines Agency's Regulatory Science to 2025 strategy has been finalized. Here, we highlight the core recommendations that stakeholders deem most significant to advance evidence generation.

AB - After 3 years of co-design with stakeholders and EU regulatory partners, the European Medicines Agency's Regulatory Science to 2025 strategy has been finalized. Here, we highlight the core recommendations that stakeholders deem most significant to advance evidence generation.

KW - Regulation

KW - Medicines

KW - Intellectual Property

KW - Science

KW - R&D

KW - European Union

U2 - 10.1038/d41573-020-00032-0

DO - 10.1038/d41573-020-00032-0

M3 - Comment/Letter to the editor

C2 - 32235873

SN - 1474-1776

VL - 19

SP - 293

EP - 294

JO - Nature Reviews Drug Discovery

JF - Nature Reviews Drug Discovery

IS - 5

ER -

A future for regulatory science in the European Union: the European Medicines Agency's strategy

Abstract

JEL classifications

Keywords

Access to Document

Fingerprint

Cite this